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Background: The purpose of this study is to compare the in-hospital mortality rates between septic patients receiving
statins and those that did not prior to developing sepsis. We compared subgroups receiving atorvastatin and simvastatin
because these two drugs differ in their pharmacologic properties.
Methods: This study was a retrospective analysis of patients selected from an institutional data base of patients
hospitalized with sepsis. The study patients were drawn from a data base of 1,961 hospitalized patients with
sepsis and included patients who met selection criteria and who were studied for HMG-CoA reductase inhibitor
(statin) use both prior to and during hospitalization. The in-hospital mortality rates of patients receiving statins
and those that did not prior to developing sepsis were compared. In-hospital mortality rates of patient
subgroups receiving atorvastatin and simvastatin were also compared. A multivariable analysis was conducted
with in-hospital mortality as the outcome variable and with multiple risk factors to include atorvastatin and
simvastatin use.
Results: The mortality rate for 359 patients receiving statins prior to hospitalization for sepsis was not significantly
different than that for 1,302 patients who did not receive pre-hospital statins (26.5% versus 30.4%, p > 0.05). The
mortality rate for 92 patients who had received atorvastatin prior to hospitalization was significantly less than that
of 253 patients who received simvastatin (18.5% versus 30.0%, p = 0.032). The use of atorvastatin prior to sepsis was
independently associated with lower in-hospital mortality in a multivariable analysis of sepsis risk factors (p = 0.021,
OR = 0.455). Patients who received atorvastatin prior to hospitalization for sepsis and had statins continued in
hospital had a very low mortality rate that was significantly less than that of those patients who never received
statins (15.7% versus 30.8%, p = 0.007).
Conclusions: Pre-hospital atorvastatin use was associated with improved in-hospital mortality in septic patients when
compared with pre-hospital simvastatin use and was independently associated with an improved outcome when
compared to other sepsis risk factors. The effect of statins in patients with sepsis may be different for individual statins.
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Sepsis and septic shock are formidable medical prob-
lems that challenge physicians caring for critically ill
patients. Today, sepsis is one of the leading causes of
morbidity and mortality with thousands of persons
suffering from these conditions on a daily basis [1-4].
It has long been recognized that early and aggressive
antibiotic treatment reduces mortality from sepsis [5].
Recent advances in resuscitation strategy and methods
have also led to improved sepsis outcomes [6]. These
advances have been embraced by the medical commu-
nity and incorporated into guidelines and policy state-
ments [7]. Despite these accomplishments, sepsis
mortality remains high, with rates between 20% and
30% [8].
Sepsis is characterized by a complex, pleiotropic in-
flammatory response [8]. Amelioration of the inflamma-
tory cascade in sepsis might be expected to have an
impact on the clinical course and outcomes of the pa-
tient with sepsis. However, previous efforts to design
treatment strategies to modify or disrupt the inflamma-
tory cascade in the septic patient have been largely un-
successful [9]. Statins are agents which have been
observed to have important anti-inflammatory effects
and to modulate the immune system response in a var-
iety of ways during sepsis [10]. There has been specula-
tion that the administration of statins may alter the
inflammatory response to infection, suggesting that they
may represent a potentially important adjunct to therapy
[11]. Data suggests that critically ill patients may benefit
from statins, and observational and retrospective studies
have suggested that patients taking statins prior to the
development of sepsis may have improved sepsis out-
comes [12-14]. However, a recent large, prospective,
multicenter study in patients with acute respiratory dis-
tress syndrome (ARDS) due to sepsis failed to demon-
strate improved outcomes following the administration
of rosuvastatin [15].
Though often considered together as a group, individ-
ual statins have unique biological properties. Statins are
lipophilic to varying degrees, which may alter their indi-
vidual effects. In addition, statins have recently been
shown to have differential antibacterial properties
in vitro, with atorvastatin having more prominent anti-
bacterial effects than other statins [16]. We postulated
that individual statins may have an agent-specific effect
on outcomes in patients with sepsis and septic shock.
We conducted a retrospective review of an institutional
data base of patients with severe sepsis. Most patients in
our institution who had received statins prior to
hospitalization for sepsis had received either atorvastatin
or simvastatin. We therefore compared the inpatient
mortality rate of patients who had received atorvastatin
to those who had received simvastatin.Methods
Study design and enrollment
All patients at our institution who developed sepsis after
January, 2005, had medical data entered into an institu-
tional sepsis quality improvement data base. Patients ad-
mitted to the intensive care units with a diagnosis of
sepsis, as well as those who developed sepsis during the
course of their hospital stay for another diagnosis, were
included in the data base. Patients with severe sepsis at
our institution were transferred to the intensive care
units and managed in this venue. We retrospectively
reviewed data that was prospectively collected between
January 1, 2005, and June 30, 2010. We additionally ex-
amined data from the institutional electronic medical
record (EMR) and the hospital pharmacy data base for
all patients enrolled in the sepsis data base. The study
was performed at a quaternary health care system lo-
cated in the Midwest United States. The study protocol
was approved as an exempt protocol by the local institu-
tional review board (IRB) project number 6870. The
need for informed consent was waived.
Patient episodes were identified as those patients en-
tered into the sepsis data base where the diagnosis of
sepsis was confirmed by a retrospective review of the
EMR. If a potential case subject had multiple admissions
entered into the data base, only the first admission was
considered for study purposes. We reviewed the EMR
and the hospital system pharmacy data base to identify if
the patient had a record of the use of statins prior to
developing sepsis and whether they received statins dur-
ing their hospitalization for sepsis. We recorded which
statin each patient was receiving prior to and during
hospitalization. We did not have specific information
concerning the pre-hospital duration of treatment with
statins. Due to the retrospective nature of the study, we
were not able to assess pre-hospital compliance with
prescribed statin therapy. The EMR was reviewed to
identify the source of sepsis for each patient. We col-
lected data from the EMR for each patient concerning
comorbid conditions. The information for each study
subject was entered into a research data base without
patient identifiers for analysis.
Definitions
Sepsis was defined as being present if a patient mani-
fested at least two of four systemic inflammatory re-
sponse syndrome criteria and had documented evidence
of infection [17]. Time 0 was defined as the point in
time when the sepsis bundle was initiated for each
study subject. Intubation was defined as endotracheal
intubation and mechanical ventilation within 24 h of
time 0. In-hospital mortality was defined as death
from any cause during the hospitalization prior to dis-
charge. Time to antibiotics was defined as the elapsed
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to the initial administration of antibiotics.
We performed all statistical analysis using SPSS soft-
ware version 18 with a logistical regression add-on pack-
age version 20 (IBM, Armonk, NY, USA) and considered
p < 0.05 to be statistically significant unless otherwise
specified. We used chi-squared tests for univariate ana-
lysis of dichotomous variables and two-sample t tests or
Mann-Whitney U tests as appropriate for univariate ana-
lysis of continuous variables. Adjustments were not
made for multiple comparisons. Where mean variables
are listed, such data includes the standard deviation
(mean ± standard deviation).
We developed a model to identify risk factors for mor-
tality by multivariable logistic regression analysis in the
subject populations. Potential risk factors were identified
from a univariable analysis of each of the available vari-
ables using mortality as the dependent variable. Vari-
ables were selected for analysis if they were significantly
associated with mortality (p < 0.05) and if at least 80% of
the case and control subjects had data available for the
variable.
Results
Clinical data were collected in a data base of patients
with sepsis for 1,965 patient episodes of sepsis between
January 1, 2005, and December 31, 2010. From these pa-
tient episodes, we selected 1,661 patient episodes of sep-
sis for study based upon the criteria described in the
‘Methods’ section (Figure 1). Exclusions included subse-
quent patient episodes after the first in patients with
multiple sepsis events (the majority) and those where
demographic data was incomplete. Of these patients,
58% were transferred to the ICU from the emergency
department, 12% were transferred to the ICU from a
general medical or surgical ward, and 29% were active
patients in the ICU when sepsis was diagnosed. PatientsFigure 1 Organizational flowchart of patient episodes categorized by pre-hreceived initiation of sepsis care as soon as sepsis was
identified, regardless of the venue of care. Of the 1,661
patient episodes investigated, 1,170 resulted in survival
to hospital discharge while 491 led to in-hospital death
from all causes, providing an overall in-hospital mortal-
ity rate of 29.6% for the investigated population
(Figure 1). The mean age (±standard deviation) for the
population was 63 (±17) years, and the mean APACHE
II score (±standard deviation) was 19 (±7). Male patients
(53%) outnumbered female patients in our population.
Overall, 44.4% of patients received vasoactive agents to
support blood pressure, and 48.4% of patients were intu-
bated and received mechanical ventilation within the
first 24 h of sepsis. The primary sources of infection are
listed in Table 1.
There were 359 patients who received statins prior to
hospitalization for sepsis. The in-hospital mortality rate
for patients who received pre-hospital statins was not
significantly different from the mortality rate for those
patients not receiving pre-hospital statins (26.5% versus
30.4%, p = 0.146, Figure 2). We chose to compare the
group of patients receiving pre-hospital atorvastatin to
those receiving simvastatin. The demographic and
clinical characteristics of these two groups were very
similar (Table 2). Among the patients who received
pre-hospital statins, 92 patients received atorvastatin,
while 253 received simvastatin (Figure 1). Seventeen pa-
tients receiving pre-hospital atorvastatin died (18.5%),
compared with 76 in the simvastatin group (30.0%),
a difference which achieved statistical significance
(p = 0.032, Figure 2). The atorvastatin group also had a
significantly lower mortality rate than did those patients
not receiving pre-hospital statins (n = 1,302, mortality
rate = 30.4%, p = 0.015). We had dosing information
available for all patients receiving pre-hospital simva-
statin and atorvastatin. The mortality difference be-
tween groups of patients receiving different doses ofospital statin use and in-hospital mortality.
Table 1 Sources of infection
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lation of patients who did not receive pre-hospital
statins, did not achieve significance. For atorvastatin,
5 of the 13 patients prescribed 10 mg of atorvastatin
daily died, providing a mortality rate of 38.5%, which
compares unfavorably with that of the 79 patients re-
ceiving higher doses of atorvastatin (15.2%, p = 0.045).
In addition to those patients noted who had received
atorvastatin or simvastatin, six received lovastatin, five
received rosuvastatin, and two received pravastatin.
One patient had reported statin use, but the specific
agent used was not determined. Two patients died
who had received lovastatin, one patient died of the
two receiving pravastatin, and no patients receiving
rosuvastatin died.Figure 2 Comparison of in-hospital mortality between patient cohorts.
*Pre-hospital atorvastatin vs pre-hospital simvastatin, p value = 0.032
(chi-square); pre-hospital atorvastatin vs no pre-hospital statin,
p = 0.015 (chi-square).In order to determine if the use of atorvastatin or sim-
vastatin in the pre-hospital setting was an independent
risk factor associated with mortality, we performed first
a univariable followed by a multivariable analysis of po-
tential risk factors, using mortality as the dependent
variable. All 1,661 patient episodes were included in the
analysis. We chose a total of 32 potential risk factors to
study by univariable analysis, including all the variables
listed in Table 2 plus three additional risk factors: pre-
hospital atorvastatin use, pre-hospital simvastatin use,
and pre-hospital statin use. Pre-hospital atorvastatin was
significantly associated with reduced mortality (p =
0.018), whereas pre-hospital simvastatin was not (p =
0.856) in the univariable analysis. Risk factors that were
significantly associated with mortality (p < 0.05) in the
univariable analysis and for which data was available for
at least 80% of patient episodes were included in the
multivariable analysis. The results of the multivariable
analysis are presented in Table 3. We determined that
pre-hospital atorvastatin use was significantly and inde-
pendently associated with improved mortality in septic
patients (p = 0.021, OR = 0.455).
Of the 1,302 patients that did not receive pre-hospital
statins, 61 patients received statins after hospitalization.
The mortality rate of the patients receiving statins in
hospital but not before hospitalization was less than that
of patients who never received statins, but this difference
did not reach significance (23% versus 30.8% respect-
ively, p = 0.222). Of the patients who received statins
only in hospital, twenty-nine of these patients received
atorvastatin with eight such patients expiring (mortality
rate = 27.6%).
Of the 359 patients who received statins prior to
hospitalization, 267 had such therapy continued in hos-
pital. The patients who received statins both prior to
hospitalization and during hospitalization had an in-
hospital mortality rate of 24.7% compared with a rate of
31.5% for patients who had received statins prior to
hospitalization but had this therapy discontinued (not
significant, p = 0.209).
Of the 92 patients who received atorvastatin prior to
hospitalization, 70 patients had statins continued in
hospital (9 patients received simvastatin rather than
atorvastatin in-hospital). These 70 patients had a mor-
tality rate of 15.7%, which was significantly different
from the population of patients that had never re-
ceived statins (p = 0.007) and was less than but not
significantly different from the mortality rate of the 22
patients that had received atorvastatin in the pre-
hospital setting and then who did not receive statins
in hospital (27.2%, p = 0.223). There were 60 patients
who received only atorvastatin both prior to and dur-
ing hospitalization; 9 of these patients died, providing
a mortality rate of 15%.
Table 2 Comparisons between groups defined by pre-hospital statin use
Variable Atorvastatin Simvastatin Significance* No statins Significance#
Number of patients 92 253 1,302
Mean age (years) 67 ± 15 69 ± 13 p = 0.365a 61 ± 17 p = 0.001a
Gender (male/female) 40/52 130/123 p = 0.194b 700/602 p = 0.056b
Mean temperature, time 0 (°C) 37.3 ± 1.5 37.2 ± 1.6 p = 0.766a 37.1 ± 1.5 p = 0.436a
Mean heart rate, time 0, (beats per min) 106 ± 22 107 ± 25 p = 0.860a 112 ± 25 p = 0.033a
Mean respiratory rate, time 0 (breaths per min) 24 ± 8 24 ± 9 p = 0.512a 25 ± 9 p = 0.351a
Mean arterial pressure, time 0 (mmHg) 76 ± 22 75 ± 22 p = 0.797a 76 ± 22 p = 0.974a
Mean arterial pH, time 0 7.34 ± 0.13 7.36 ± 0.12 p = 0.169a 7.35 ± 0.13 p = 0.577a
Mean creatinine, time 0 (mg/dL) 3.5 ± 3.0 3.1 ± 2.6 p = 0.357c 2.7 ± 2.9 p = 0.003c
Mean leukocyte count, time 0 (K/μL) 14.7 ± 9.3 16.5 ± 12.7 p = 0.225a 16.1 ± 17.0 p = 0.459a
Mean hematocrit, time 0 (%) 32.6 ± 6.8 32.3 ± 6.5 p = 0.688a 32.9 ± 15.1 p = 0.860a
Mean platelet count, time 0 (K/μL) 242 ± 124 238 ± 130 p = 0.813a 230 ± 143 p = 0.431a
Mean bilirubin, time 0 (mg/dL) 1.2 ± 1.8 1.1 ± 2.1 p = 0.755a 1.6 ± 3.1 p = 0.221a
Mean lactate (mmol/L) 3.2 ± 2.8 3.6 ± 3.2 p = 0.454c 4.0 ± 3.4 p = 0.011c
Mean APACHE II, time 0 18.8 ± 6.5 19.4 ± 7.1 p = 0.484a 18.6 ± 7.4 p = 0.833a
Time to antibiotics (min) 190 ± 152 166 ± 155 p = 0.300a 195 ± 226 p = 0.862a
Mean fluid volume administered, first 24 h (L) 4.542 ± 3.166 5.402 ± 3.348 p = 0.036a 4.955 ± 4.477 p = 0.393a
Mean first CVP value (cm H2O) 12 ± 6 11 ± 6 p = 0.361
a 10 ± 6 p = 0.123a
Median glucose, first 24 h (mg/dL) 142 ± 82 143 ± 56 p = 0.962a 134 ± 67 p = 0.226a
Mixed venous oxygen saturation (%) 71 ± 12 70 ± 15 p = 0.737a 70 ± 16 p = 0.753a
Use of vasopressors, number (%) 41 (44.6%) 115 (45.5%) p = 0.883b 576 (44.2%) p = 0.952b
Intubation, first 24 h, number (%) 37 (40.2%) 118 (46.6%) p = 0.289b 641 (49.2%) p = 0.095b
Dialysis, number (%) 7 (7.6%) 24 (9.5%) p = 0.590b 48 (3.7%) p = 0.062b
Abdominal source, number (%) 13 (14.1%) 29 (11.5%) p = 0.503b 172 (13.2%) p = 0.823b
Lung source (%) 27 (29.3%) 83 (32.8%) p = 0.542b 396 (30.4%) p = 0.314b
Urologic source (%) 16 (17.4%) 52 (20.6%) p = 0.514b 192 (14.7%) p = 0.872b
History of neoplasia (%) 16 (17.4%) 67 (26.5%) p = 0.081b 334 (25.7%) p = 0.077b
History of cardiac disease (%) 72 (78.3%) 196 (77.4%) p = 0.876b 690 (53.0%) p < 0.0001b
History of chronic kidney disease (%) 51 (55.4%) 131 (51.8%) p = 0.547b 410 (31.5%) p < 0.0001b
History of liver disease (%) 9 (9.8%) 20 (7.9%) p = 0.578b 252 (19.4%) p = 0.023b
Mortality (%) 17 (18.5%) 76 (30.0%) p = 0.032b 396 (30.4%) p = 0.015b
*Comparison between patients receiving atorvastatin or simvastatin prior to hospitalization; #comparison between patients receiving atorvastatin or no statins
prior to hospitalization. aStudent’s t test; bchi-square test; cMann-Whitney U test. Values achieving significance are italicized.
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The most important finding in our study is that pre-
hospital atorvastatin use was significantly associated
with reduced mortality during a hospitalization for sepsis
when compared to pre-hospital simvastatin use. Pre-
hospital administration of atorvastatin was an independ-
ent factor associated with improved mortality in our
septic population despite the fact that statins as a class were
not associated with improved mortality when administered
prior to hospitalization. Patients who received atorvastatin
prior to a hospitalization for sepsis, and had statins contin-
ued in hospital, had a very low mortality rate that was sig-
nificantly different than patients who never received statinsand less than but not significantly different than patients
who only received atorvastatin in the pre-hospital setting.
Some, but not all, prior studies suggest that administration
of statins prior to the development of sepsis may improve
sepsis outcomes [12,18,19]. Little work has been done in
this regard concerning individual statin agents.
Although the focus of our investigations was statin use
in septic patients, we also made observations concerning
other sepsis mortality risk factors. Risk factors in our pa-
tients significantly associated with increased mortality,
and those which have been observed by other investiga-
tors to be associated with increased mortality during
severe infection include thrombocytopenia [20], high
Table 3 Multivariable analysis of the association of
clinical risk factors with mortality
Risk factor Significance Odds ratio
Platelet count, time 0 p = 0.001 0.998
Lactate value p < 0.0001 1.083
APACHE II p < 0.0001 1.038
Glucose level p = 0.091 0.998
Male gender p = 0.073 1.273
Vasopressor use p < 0.0001 1.678
Mechanical ventilation p < 0.0001 2.114
Urologic source of infection p < 0.0001 0.434
Oncologic past history p = 0.045 1.355
Atorvastatin use prior to sepsis p = 0.021 0.455
Age p = 0.003 1.013
Temperature, time 0 p = 0.091 0.928
Mean arterial pressure, time 0 p = 0.459 0.998
Leukocyte count, time 0 p = 0.071 1.010
Hematocrit, time 0 p < 0.0001 0.956
Arterial pH p = 0.342 1.796
Ouellette et al. Annals of Intensive Care  (2015) 5:9 Page 6 of 8lactate levels [21], APACHE II score [22,23], vasopressor
use [23,24], mechanical ventilation [23,25], a past history
of cancer [26], age [23], and anemia [27]. We noted that
having a urologic source of sepsis, as opposed to other
sources of infection, was associated with a protective ef-
fect against mortality, which has also been previously
observed [28].
Recent studies have tempered the early enthusiasm for
the role of statins in the treatment of sepsis [29]. Janda and
coworkers performed a systemic review and meta-analysis
of 20 studies, including prospective, retrospective, observa-
tional, and cohort studies [19]. A protective effect of statins
compared with placebo was demonstrated for a variety of
infectious outcomes, but the analysis was very limited by
the quality of the studies. Pasin and colleagues assessed five
prospective, placebo-controlled studies involving statins in
a meta-analysis and found that there was no evidence of a
difference in mortality or hospital stay [30]. Wan and asso-
ciates evaluated both prospective, controlled studies and
observational studies [31]. Among five prospective, ran-
domized, controlled studies, there was no demonstrable
change in in-hospital or 28-day mortality. However, among
27 observational studies, there was a significant decrease in
mortality noted. A recent large, multicenter, prospective,
randomized, and controlled study comparing rosuvastatin
to placebo in patients with ARDS due to sepsis failed to
demonstrate a mortality benefit for rosuvastatin use [15]. In
our study, we found that pre-hospital statin use generally
did not change outcomes, though atorvastatin was associ-
ated with reduced mortality.Statins are commonly used as lipid-lowering agents.
Although often considered as a class, statins vary be-
tween agents in terms of their chemical structure and
properties and have different pharmacodynamics [32].
While some statins have been derived from fungal me-
tabolites, others, such as atorvastatin, are completely
synthetic. Statins vary considerably in terms of their
lipophilicity, first-pass metabolism, half-life, and bio-
availability. Metabolism of statins varies among agents,
and activity at the active site of the enzyme HMG-
CoA reductase is subtly different for different statins.
Because of these chemical and pharmacological differ-
ences between statins, different biological effects might be
anticipated.
Statins have been postulated to have an effect on sep-
sis outcomes that is mediated by their anti-inflammatory
effects [10,11]. Recent evidence has suggested that
statins also may have direct antimicrobial properties.
Masadeh and colleagues studied the in vitro antimicro-
bial effect of statins on 16 common bacterial strains,
including both gram-positive and gram-negative bac-
teria, finding evidence that different statins had varying
antimicrobial effects [16]. While both atorvastatin and
simvastatin were more potent than rosuvastatin with
respect to many gram-positive agents, selected gram-
negative organisms were more sensitive to atorvastatin than
either simvastatin or rosuvastatin. However, it should be
noted that the minimum inhibitory concentrations for ator-
vastatin, in particular, in the work by Masadeh, exceed by at
least 100-fold the maximum serum concentration for this
agent seen in human subjects with standard dosing [33].
This fact limits the extrapolation of Masadeh’s in vitro data
to a clinical effect in sepsis.
Individual statins have not been directly compared
with respect to clinical outcomes from infection. We
assessed the 27 observational studies highlighted in the
comprehensive review by Wan [31], finding that 15 did
not distinguish between the types of statins used, and 1
study reported simvastatin use. Of the 11 studies report-
ing and specifying the individual statins used, none
directly compared clinical outcomes between statins.
Prospective studies to date have compared individual
statins to placebo, but not to other statins. Our work
represents the first comparison of in-hospital mortality
rates in septic patients treated prior to hospitalization
with two different statins, with the finding of improved
mortality associated with atorvastatin compared to
simvastatin.
Statins have beneficial effects on lipid profiles and car-
diovascular outcomes and are generally well tolerated in
stable outpatients. Despite the possible beneficial effects
noted in this work in patients with sepsis, statins may
have adverse effects which could complicate their use,
especially in the critically ill patient. Rhabdomyolysis
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Statins are metabolized by the cytochrome P450 system
in the liver, and liver disease, a common occurrence in
the critically ill, affects the metabolism of these agents
and increases the risk of muscle disease [32]. Food in-
take has a variable effect on statin bioavailability, which
may have important consequences in the critically ill pa-
tient that is unable to receive oral nutrition [32]. Statins
are highly protein bound, a fact that may well be import-
ant in the critically ill patient [32]. Interruption of
chronic outpatient therapy in a critically ill patient could
lead to augmentation of cardiovascular risk [14]. We did
not have specific information concerning potential ad-
verse effects from statins, including cause-specific mor-
tality and cardiovascular morbidity, which limits our
study in recommendations concerning statin utility in
sepsis.
Our study has a number of important limitations. Our
work is from a single center and is retrospective and ob-
servational. We did not have information about pre-
hospital duration of statin therapy, nor did we have in-
formation concerning patient compliance with pre-
scribed pre-hospital statin treatments. While most of
our patients had health insurance, the lack of coverage
for some patients creates the possibility of treatment bias
along demographic lines within our population. In
addition, insurance policies provide economic advan-
tages for the use of specific agents within a class, a fact
which clearly has implications for our study. Given the
volatile and changing insurance environment within the
United States during the period in question, we have no
ability in our retrospective study to completely account
for these effects. We performed multiple comparisons in
analyzing our data without adjustment, increasing the
likelihood of false-positive associations. However, we
note that there was little difference between the group
of patients receiving atorvastatin and those receiving
simvastatin, except for the total volume of fluid received
during resuscitation. While resuscitation with intraven-
ous fluid and other agents to defined clinical goals is an
important element of sepsis management, we have previ-
ously demonstrated in our patients that the total amount
of fluid administered in the first 24 h of the initial resus-
citation is not an independent risk factor for adverse
clinical outcomes [34].
Conclusions
Pre-hospital atorvastatin use by patients developing sep-
sis was associated with reduced in-hospital mortality
when compared to the use of pre-hospital simvastatin.
Pre-hospital atorvastatin was independently associated
with an improved mortality rate when controlling for
other sepsis risk factors in a population of septic pa-
tients. We postulate that atorvastatin may have uniquebiochemical, pharmacodynamic, and antimicrobial ef-
fects compared with other statins that may account for
the observed amelioration in mortality rates. Further
study of the effects of individual statin agents in patients
with sepsis is needed to confirm this hypothesis.
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